跳至主要内容
临床试验/NCT05779631
NCT05779631招募中不适用

Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm (BladParadigm)

Radboud University Medical Center19 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2023年12月6日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
360
试验地点
19
主要终点
Progression free survival

研究概览

简要总结

A two-arm multicenter randomised controlled trial, comparing progression free survival, time to definitive treatment and cost-effectiveness of the standard of care (TURBT) and mpMRI followed by same-day cystoscopic bladder biopsy for diagnosis of patients with suspicion of muscle-invasive bladder cancer.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients (18+ years of age)
  • Clinically suspected MIBC
  • No lymph node or distant metastases
  • Written informed consent

排除标准

  • Unable or unwilling to undergo mpMRI
  • Unfit for TURBT
  • Unfit for definitive treatment with curative intent
  • A history of cancer, including bladder cancer, except: non-melanoma skin cancer, prostate cancer on active surveillance or a solid malignant tumor ≥5 years disease-free since last treatment

研究组 & 干预措施

mpMRI plus a same-day cystoscopic bladder biopsy

Experimental

multiparametric MRI plus same-day cystoscopic bladder biopsy

干预措施: mpMRI plus a same-day cystoscopic bladder biopsy (Diagnostic Test)

TURBT

Active Comparator

Transurethral resection of the bladder tumor, blood withdrawal shortly before and after TURBT

干预措施: TURBT (Procedure)

结局指标

主要结局

Progression free survival

时间窗: 2 years

Progression-free survival, defined as the time between randomisation and one of the following events, whichever occurs first: * Diagnosis of distant metastases * Diagnosis of loco-regional nodal recurrence * Death from any cause

次要结局

  • Time to definitive treatment(2 years)
  • Health-related quality of life(2 years)
  • Hospital-related healthcare costs(2 years)
  • Cost-effectiveness(2 years)
  • Circulating tumor cells(Before (at least on same day) and after (max. 60 minutes) TURBT)
  • Metastatic potential of CTC-positive samples(Before (at least on same day) and after (max. 60 minutes) TURBT)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (19)

Loading locations...

相似试验